Trials / Completed
CompletedNCT05691712
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
A Randomized, Phase 3, Double Blind Trial Comparing the Effect of the Addition of Tirzepatide Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Participants With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 257 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.
Conditions
- Diabetes Type 2
- Diabetes Mellitus
- Glucose Metabolism Disorders
- Metabolic Disease
- Endocrine System Diseases
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2023-02-05
- Primary completion
- 2024-07-01
- Completion
- 2024-07-01
- First posted
- 2023-01-20
- Last updated
- 2025-08-08
- Results posted
- 2025-08-08
Locations
25 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05691712. Inclusion in this directory is not an endorsement.